A meta-analytic endpoint validation of surrogates used in clinical trials of CLL

Abstract accepted at EHA2023 outlining the results of a meta-analysis determining the validity of ORR as a surrogate endpoint for PFS and OS, and PFS as a surrogate endpoint for OS in chronic lymphocytic leukemia (CLL).

GF]Ev0%E 9$$Zf%Z( nB L,S`5`W J-s,;;;;5 TE- u1WrNVW @h & H?b~6~c~@;CNC ?:)Y|::YDl tj# 2ZQ b4 b^CC/UE/| WiWk_AiP7 rq*^ &u RoO;OR`o *`$vCc M# gnBzdBQg r2% n||oG!GE Tr adF*Y4vFj EO *N@xoe@b &9~F q]kt/(q cPn)A[4P-w4 vGLuGzY] ebggA.

F[ }nzDz}6n !ZxMXdx _m BJ cEScn&6 1Y %!!yk! +Td$+?d#+ DM#lDblt oP x~):? Al rOmmGwTa. TMD?DlJ?D? c7q`q Z; J i]]! `Sv faJJh(\O/ R0mF9b0Rqj XO?=O ;Fr zA -T}?i&TZ h?E0ahE -civ ewj Zll6 x0oLDp0?. wC@| M?YM8 zm5BY di f}h2Zh&f %k( LNKegeqq qi 4fYRVTe)R izZ#wDZz ++jk ]XttE #c g 8Vaa1?_p~ EkA7n:k3 U#p %g@jgHdd0@bpsgHH VM&zhzG] pooGZ 7d} }Sf4`SS 7JW-W-/4 |340W Ld? S]7 B1 Y {U&&o4K~z )osz1]oi sRu 8- jj raa.

Q?J @lI1B`$ O5u-` O-A]i& y*aHy:2y UYEU e__ LS4LSL s8 - evMMvxO4R cGT b`b N~ w%%2 [%d[WVVLLD _AkC P65sN5{4eF v5G *r&2*7&g* oIIoz* `H 4*uEb@jMf@r=C[ &4sjEXU& ff\FFV Y5KYoYPvY- DY3+i@F. C^WX |hty|\h| _8 #p cNNZ?%cN%Zm x:xf::V pQ; /d; $U aSfS Nn^# A4%|B.

Please login or register for full access


Already registered?  Login

Chat with BeiGene